Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

M.D., executive vice president and chief medical officer at Vertex. "We look forward to concluding our discussions with regulators and initiating phase 3 development in the first half of the year ...

outperforming the Medical sector's loss of 1.05% and the S&P 500's loss of 8.15%. The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's ...

Vertex says that: Data presented demonstrate unprecedented efficacy and curative potential. Safety data are consistent with the immunosuppressives, the perioperative period, and past medical history.

exceeding the Medical sector's loss of 1.88% and the S&P 500's loss of 7.38%. The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...